Trial Profile
A clinical study of Apatinib in treatment of patients with locally advanced or metastatic radioactive iodine (RAI) refractory differentiated thyroid carcinoma
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 03 Aug 2017
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary)
- Indications Thyroid cancer
- Focus Therapeutic Use
- 03 Aug 2017 New trial record